Safety and Tolerability of 96 Weeks of Tenofovir Disoproxil Fumarate (TDF) Treatment in HBeAg Negative and Positive Patients Infected with Chronic Hepatitis B (CHB)

被引：0
|
作者：
Jacobson, Ira M.
Marcellin, Patrick
Heathcote, Jenny
Mathurin, Philippe
Gane, Ed J.
Buggisch, Peter
Husa, Petr
Krastev, Zahary
Sorbel, Jeff
Anderson, Jane
Mondou, Elsa
Rousseau, Franck
机构：
来源：
GASTROENTEROLOGY | 2009年 / 136卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A867 / A867
页数：1
相关论文
共 50 条
  • [1] SAFETY AND TOLERABILITY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBeAg NEGATIVE AND POSITIVE PATIENTS INFECTED WITH CHRONIC HEPATITIS B (CHB)
    Marcellin, P.
    Heathcote, E. J.
    Jacobson, I.
    Mathurin, P.
    Gane, E.
    Buggisch, P.
    Husa, P.
    Krastev, Z.
    Sorbel, J.
    Anderson, J.
    Mondou, E.
    Rousseau, F.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S336 - S337
  • [2] Two year safety and tolerability of tenofovir disoproxil fumarate treatment in HBeAg negative and HBeAg positive patients with chronic hepatitis B
    Gane, E. J.
    Sievert, W.
    Weilert, F.
    George, J.
    Strasser, S. I.
    Crawford, D.
    Moyes, C.
    Heathcote, E. J.
    Marcellin, P.
    Sorbel, J.
    Rousseau, F.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2009, 24 : A309 - A309
  • [3] FOUR YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB), PRELIMINARY ANALYSIS
    Gane, Edward J.
    Lee, Samuel S.
    Heathcote, E. Jenny
    Sievert, William
    Trinh, Huy N.
    Kaita, Kelly D.
    Younossi, Zobair M.
    George, Jacob
    Marcellin, Patrick
    Coombs, Derek H.
    Anderson, Jane
    Mondou, Elsa
    HEPATOLOGY, 2010, 52 (04) : 559A - 559A
  • [4] A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96
    Agarwal, K.
    Fung, S.
    Seto, W. K.
    Lim, Y. S.
    Gane, E.
    Janssen, H. L.
    Sharma, M.
    Chuang, W. L.
    Bae, H.
    Yoon, K. T.
    Flaherty, J. F.
    Lau, A.
    Gaggar, A.
    Suri, V.
    Cathcart, A.
    Lin, L.
    Subramanian, G. M.
    Shalimar
    Furusyo, N.
    Buti, M.
    Chan, H. L.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S478 - S478
  • [5] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-NEGATIVE, CHRONIC HEPATITIS B PATIENTS: A GLOBAL PHASE 3 STUDY
    Brunetto, Maurizia Rossana
    Lim, Young-Suk
    Gane, Edward
    Seto, Wai-Kay
    Osipenko, Marina
    Ahn, Sang Hoon
    Janssen, Harry L.
    Shukla, Akash
    Chuang, Wan-Long
    Trinh, Huy N.
    Celen, Mustafa
    Flaherty, John F.
    Chan, Alain
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Subramanian, Mani
    Pan, Calvin Q.
    Izumi, Namiki
    Marcellin, Patrick
    Chan, Henry L.
    Buti, Maria
    GASTROENTEROLOGY, 2017, 152 (05) : S1086 - S1086
  • [6] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-POSITIVE PATIENTS: A GLOBAL PHASE 3 STUDY
    Agarwal, Kosh
    Fung, Scott
    Seto, Wai-Kay
    Lim, Young-Suk
    Gane, Edward
    Janssen, Harry L.
    Chuang, Wan-Long
    Bae, Ho
    Yoon, Ki Tae
    Flaherty, John F.
    Lau, Audrey
    Gaggar, Anuj
    Suri, Vithika
    Cathcart, Andrea
    Lin, Lanjia
    Chan, Alain
    Shalimar, Mani Subramanian
    Furusyo, Norihiro
    Buti, Maria
    Chan, Henry L.
    GASTROENTEROLOGY, 2017, 152 (05) : S1085 - S1086
  • [7] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
    Chan, Henry Lik Yuen
    Lim, Young-Suk
    Seto, Wai Kay Walter
    Agarwal, Kosh
    Brunetto, Maurizia R.
    Janssen, Harry L. A.
    Caruntu, Florin
    Stepanova, Tatjana
    Tsang, Owen
    Yatsuhashi, Hiroshi
    Tak, Won Young
    Chen, Chi-Yi
    Celen, Mustafa
    Suri, Vithika
    Flaherty, John F.
    Lin, Lanjia
    Cathcart, Andrea
    Gaggar, Anuj
    Pan, Calvin Q.
    Shalimar
    Buti, Maria
    HEPATOLOGY, 2018, 68 : 227A - 228A
  • [8] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
    Chan, Henry Lik-Yuen
    Buti, Maria
    Flisiak, Robert
    Ryder, Stephen
    Streinu-Cercel, Adrian
    Flaherty, John F.
    Gaggar, Anuj
    Mo, Shuyuan
    Subramanian, G. Mani
    Zoulim, Fabrian
    Andreone, Pietro
    Marcellin, Patrick
    GUT, 2018, 67 : A97 - A97
  • [9] No Detectable Resistance to Tenofovir Disoproxil Fumarate (TDF) in HBeAg plus and HBeAg- Patients with Chronic Hepatitis B (CHB) After Eight Years of Treatment
    Corsa, Amoreena C.
    Liu, Yang
    Flaherty, John F.
    Marcellin, Patrick
    Miller, Michael D.
    Kitrinos, Kathryn M.
    HEPATOLOGY, 2014, 60 : 1020A - 1020A
  • [10] Efficacy and Safety of Tenofovir Alafenamide (TAF) at 96 Weeks in Chronic HBV (CHB) Patients with Risk Factors for Use of Tenofovir Disoproxil Fumarate (TDF)
    Buti, Maria
    Stepanova, Tatjana
    Celen, Mustafa K.
    Flisiak, Robert
    Ryder, Stephen D.
    Streinu-Cercel, Adrian
    Gurel, Selim
    Flaherty, John F.
    Gaggar, Anuj
    Suri, Vithika
    Mo, Shuyuan
    Subramanian, Mani
    Nurmukhametova, Elena
    Zoulim, Fabien
    Andreone, Pietro
    Marcellin, Patrick
    HEPATOLOGY, 2017, 66 : 488A - 488A
12345